logo
welcome
The Motley Fool

The Motley Fool

Shares of Summit Therapeutics rocketed 123.4% this week. Here's why

The Motley Fool
Summary
Nutrition label

66% Informative

Summit Therapeutics' new drug Ivonescimab bested Keytruda in a phase 3 clinical trial.

Wall Street analysts hiked their price targets on Summit 's stock.

Management took advantage of Wall Street's enthusiasm to raise $235 million in an equity raise announced Thursday .

It's very difficult to know whether Summit is a buy or not at this point.

VR Score

53

Informative language

50

Neutral language

25

Article tone

formal

Language

English

Language complexity

50

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

8

https://www.fool.com/author/16731/https://www.fool.com/terms/b/blockbuster-drug/?utm_source=yahoo-host-full&utm_medium=feed&utm_campaign=article&referring_guid=8bf318ef-f5ce-42f9-a562-5fd5eaadde83https://www.fool.com/investing/2024/09/13/why-summit-therapeutics-skyrocketed-123-this-week/?utm_source=yahoo-host-full&utm_medium=feed&utm_campaign=article&referring_guid=8bf318ef-f5ce-42f9-a562-5fd5eaadde83https://api.fool.com/infotron/infotrack/click?apikey=35527423-a535-4519-a07f-20014582e03e&impression=71be5919-b0f9-4bfe-8480-fd5f9dae6696&url=https%3A%2F%2Fwww.fool.com%2Fmms%2Fmark%2Fe-foolcom-sa-bbn-dyn%3Faid%3D10993%26source%3Disaeditxt0010951%26ftm_cam%3Dsa-bbn-evergreen%26ftm_veh%3Darticle_pitch_feed_yahoo%26ftm_pit%3D16425&utm_source=yahoo-host-full&utm_medium=feed&utm_campaign=article&referring_guid=8bf318ef-f5ce-42f9-a562-5fd5eaadde83https://www.fool.com/legal/fool-disclosure-policy/https://www.fool.com/investing/2024/09/09/why-summit-therapeutics-rocketed-over-60-today/?utm_source=yahoo-host-full&utm_medium=feed&utm_campaign=article&referring_guid=8bf318ef-f5ce-42f9-a562-5fd5eaadde83https://api.fool.com/infotron/infotrack/click?apikey=35527423-a535-4519-a07f-20014582e03e&impression=71be5919-b0f9-4bfe-8480-fd5f9dae6696&url=https%3A%2F%2Fwww.fool.com%2Fmms%2Fmark%2Fe-foolcom-sa-bbn-dyn%3Faid%3D10993%26source%3Disaeditxt0010951%26ftm_cam%3Dsa-bbn-evergreen%26ftm_pit%3D16425%26ftm_veh%3Darticle_pitch_feed_yahoo%26company%3DSummit%2520Therapeutics&utm_source=yahoo-host-full&utm_medium=feed&utm_campaign=article&referring_guid=8bf318ef-f5ce-42f9-a562-5fd5eaadde83http://marketintelligence.spglobal.com/

Affiliate links

no affiliate links